



Living Cell Technologies Limited

COMPANY ANNOUNCEMENT

Living Cell Technologies Publishes Expert Opinion on Bioartificial Pancreas for Diabetes

21 April 2009 – Sydney, Australia, Auckland, New Zealand– Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) indicated that its review on the state of the art of using encapsulated porcine cells for the treatment of insulin dependent diabetes has been published in a recent issue of the science journal, *Expert Opinion on Biological Therapies*.

The scientific review is an update summarising how recent advances overcome technical hurdles to deliver insulin producing pig cells to people with diabetes in a way that evades rejection by the immune system without using toxic immune suppressive drugs.

LCT CEO, Dr Paul Tan said, "LCT's Medical Director Professor Bob Elliott and Dr Christopher Thanos, previously an employee of LCT and now an independent consultant to LCT and a Visiting Scholar at Brown University, Rhode Island, USA, are recognized experts in this field."

The review presents an overview of the long held goal of a bioartificial pancreas that is made up of cells that produce insulin for people who are not able to make their own insulin. Such cells have come from pigs because of the shortage of human donors. In the past 5 years, the scientific community have developed criteria to critically select donor animals in clean breeding facilities and which are screened against various viruses.

The authors described the many attempts to implant these pig cells in protective spheres, sheets, cylinders, rods, discs or other structures and often with immunosuppressive drugs that prevent T cells of the body's immune system from rejecting the implanted cells.

The paper tracks implants of pig islets dating to the first attempt in Sweden in 1994 with immune suppression to more recent implants in New Zealand without using immunosuppressive drugs.

Their review concludes "With advances in biomaterial design, source tissue selection and the evolution of critical cell processing techniques, contemporary encapsulated porcine islet therapies offer a new level of clinical promise.

LCT's lead product, DIABECCELL[®] comprising encapsulated neonatal porcine pancreatic islets, is presently in Phase I/IIa human clinical trial without immune suppression.

Reference: *CG Thanos, RB Elliott. Encapsulated porcine islet transplantation: an evolving therapy for the treatment of type 1 diabetes. Expert Opinion on Biological Therapies. 2009; 9 (1): 29 -44. [The full article is available from www.expertopin.com upon subscription]*

-Ends-



For further information:

Dr. Paul Tan
Chief Executive Officer
Mob: 0402 716 984 (AUS)
Mob: 021 608 784 (NZ)
Tel: +64 9 276 2690
ptan@lctglobal.com

Mr John Cowan
Finance & Administration Manager
Tel: +64 9 276 2690
jcowan@lctglobal.com

Prof. Bob Elliott
Medical Director
Mob: +64 27 292 4177
Tel: +64 9 276 2690
belliott@lctglobal.com

Rebecca Wilson
Investor and Media Relations
Mob: +61 417 382 391
Tel: +61 3 9866 4722
rwilson@bcg.com.au

About Living Cell Technologies: www.lctglobal.com

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. For Parkinson's disease, Huntington's disease and other neurological disorders, the company is developing microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of April 2009 and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.